Markets:

Overview

News

Currencies

International

Treasuries

Harmony Biosciences Holdings, Inc. - Common Stock (NQ:HRMY)

35.25 -0.61 (-1.70%)

Streaming Delayed Price Updated: 11:12 AM EDT, Jul 30, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Harmony Biosciences Holdings, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

Harmony Biosciences Holdings (NASDAQ:HRMY) – A Strong Growth Stock at a Reasonable Valuation ↗

June 06, 2025

Harmony Biosciences (HRMY) offers strong growth, solid profitability, and an attractive valuation, making it a standout in the pharmaceuticals sector.

Via Chartmill

Harmony Biosciences Strengthens Patent Position With Favorable Settlement in ANDA Litigation

June 05, 2025

From Harmony Biosciences Holdings, Inc.

Via Business Wire

Harmony Biosciences to Participate in Goldman Sachs 46th Annual Global Healthcare Conference

June 04, 2025

From Harmony Biosciences Holdings, Inc.

Via Business Wire

Where Harmony Biosciences Hldgs Stands With Analysts ↗

June 02, 2025

Via Benzinga

Harmony Biosciences Holdings ([NASDAQ:HRMY](https://www.chartmill.com/stock/quote/HRMY/profile)) – A Strong Growth Stock with Technical Breakout Potential ↗

May 29, 2025

Harmony Biosciences (HRMY) shows strong growth, profitability, and a bullish technical pattern, making it a stock worth watching in the pharmaceuticals sector.

Via Chartmill

Earnings Scheduled For May 6, 2025 ↗

May 06, 2025

Via Benzinga

Harmony Biosciences's Earnings: A Preview ↗

May 05, 2025

Via Benzinga

Demystifying Harmony Biosciences Hldgs: Insights From 11 Analyst Reviews ↗

February 27, 2025

Via Benzinga

Harmony Biosciences Holdings (NASDAQ:HRMY) – A Potentially Undervalued Stock with Strong Fundamentals ↗

May 21, 2025

Harmony Biosciences (HRMY) shows strong growth, profitability, and financial health while trading at an attractive valuation, making it a potential pick for value investors.

Via Chartmill

HARMONY BIOSCIENCES HOLDINGS (NASDAQ:HRMY) - A Strong Candidate for Affordable Growth Investors ↗

May 15, 2025

HARMONY BIOSCIENCES HOLDINGS (NASDAQ:HRMY) offers strong growth, reasonable valuation, and solid financial health, making it an attractive option for investors seeking affordable growth stocks.

Via Chartmill

Deep Dive Into Harmony Biosciences Hldgs Stock: Analyst Perspectives (13 Ratings) ↗

May 06, 2025

Via Benzinga

Harmony Biosciences Reports Strong Q1 2025 Financial Results, Highlights Advancement of Its Pipeline and Upcoming Catalysts, and Reaffirms 2025 Revenue Guidance

May 06, 2025

From Harmony Biosciences Holdings, Inc.

Via Business Wire

Harmony Biosciences Holdings (NASDAQ:HRMY) – A Strong Affordable Growth Stock ↗

May 02, 2025

Harmony Biosciences Holdings (NASDAQ:HRMY) is a strong affordable growth stock with high growth, solid profitability, and attractive valuation. Learn why it stands out in the pharmaceutical sector.

Via Chartmill

Harmony Biosciences Holdings (NASDAQ:HRMY) – A Strong Affordable Growth Stock Candidate ↗

April 30, 2025

Harmony Biosciences Holdings (NASDAQ:HRMY) – A Strong Affordable Growth Stock Candidate

Via Chartmill

HARMONY BIOSCIENCES HOLDINGS (NASDAQ:HRMY) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. ↗

April 29, 2025

Uncover the potential of HARMONY BIOSCIENCES HOLDINGS, an undervalued stock. NASDAQ:HRMY maintains a strong financial position and offers an appealing valuation.

Via Chartmill

Harmony Biosciences to Report First Quarter 2025 Financial Results on May 6, 2025

April 29, 2025

From Harmony Biosciences Holdings, Inc.

Via Business Wire

HARMONY BIOSCIENCES HOLDINGS (NASDAQ:HRMY) is not too expensive for the growth it is showing. ↗

April 24, 2025

Discover HARMONY BIOSCIENCES HOLDINGS, an undervalued growth gem. NASDAQ:HRMY is shining in terms of growth metrics, and it's also displaying strong financial health and profitability, retaining an...

Via Chartmill

Breaking Down Harmony Biosciences Hldgs: 13 Analysts Share Their Views ↗

April 08, 2025

Via Benzinga

Harmony Biosciences Presents Promising Open-Label Extension Data of ZYN002 in Fragile X Syndrome

April 08, 2025

From Harmony Biosciences Holdings, Inc.

Via Business Wire

Friday's pre-market session: top gainers and losers ↗

April 04, 2025

As the US market prepares to open on Friday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.

Via Chartmill

In the world of growth stocks, HARMONY BIOSCIENCES HOLDINGS (NASDAQ:HRMY) shines as a value proposition. ↗

April 03, 2025

HARMONY BIOSCIENCES HOLDINGS was identified as a growth stock that isn't overvalued. NASDAQ:HRMY is excelling in various growth indicators while maintaining a solid financial footing.

Via Chartmill

Harmony Biosciences Appoints Biotech Leader Ron Philip to Its Board of Directors

April 03, 2025

From Harmony Biosciences Holdings, Inc.

Via Business Wire

HARMONY BIOSCIENCES HOLDINGS (NASDAQ:HRMY): a strong growth stock preparing for the next leg up?. ↗

March 28, 2025

Based on a technical and fundamental analysis of NASDAQ:HRMY we can say: HARMONY BIOSCIENCES HOLDINGS (NASDAQ:HRMY)—Positioned as a High-Growth Stock, Ready for a Potential Breakout.

Via Chartmill

Harmony Biosciences to Participate in 24th Annual Needham Virtual Healthcare Conference

March 26, 2025

From Harmony Biosciences Holdings, Inc.

Via Business Wire

Harmony Biosciences Names Adam Zaeske as Chief Commercial Officer to Lead the Next Phase of Commercial Growth as Its Portfolio Expands

March 24, 2025

From Harmony Biosciences Holdings, Inc.

Via Business Wire

HRMY Investors Have Opportunity to Join Harmony Biosciences Holdings, Inc. Fraud Investigation with the Schall Law Firm

March 21, 2025

From The Schall Law Firm

Via Business Wire

Expert Outlook: Harmony Biosciences Hldgs Through The Eyes Of 11 Analysts ↗

March 18, 2025

Via Benzinga

HARMONY BIOSCIENCES HOLDINGS (NASDAQ:HRMY), a growth stock which is not overvalued. ↗

March 12, 2025

Via Chartmill

Harmony Biosciences to Participate in Upcoming Investor Conferences

March 04, 2025

From Harmony Biosciences Holdings, Inc.

Via Business Wire

Don't overlook HARMONY BIOSCIENCES HOLDINGS (NASDAQ:HRMY)—it's a hidden gem with strong fundamentals and an attractive price tag. ↗

February 27, 2025

When you look at HARMONY BIOSCIENCES HOLDINGS (NASDAQ:HRMY), it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.

Via Chartmill

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.